25.03.2024 • NewsSchottSchott Pharmainvestment

Schott Pharma to Build New US Prefillable Syringe Manufacturing Facility

In a move to triple its production of glass and polymer syringes for the US market by 2030, Germany’s Schott Pharma announced plans to build its first US facility to manufacture prefillable polymer syringes that meet the need for deep-cold storage and transportation of mRNA medications.

In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity.

The project, Schott Pharma said, will create 401 jobs and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027.

“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, Schott Pharma will be able to fill those orders quickly and efficiently here in the US,” said Andreas Reisse, CEO of Schott Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain,” Reisse added.

Rendering of new planned Schott Pharma manufacturing facility in Wilson, North...
Rendering of new planned Schott Pharma manufacturing facility in Wilson, North Carolina. Source: Schott Pharma

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.